25 reports

  • 4.1 BIBLIOGRAPHY

HIGH-RISK PATIENTS ARE TYPICALLY GIVEN ANTIVIRALS SUCH AS VALGANCICLOVIR FOR PROPHYLAXIS OR AS PRE-EMPTIVE THERAPY (HODSON ET AL., 2013).

  • Transplantation
  • Japan
  • North America
  • United States
  • Forecast

You can easily book an appointment with one online.

  • Transplantation
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

THE TEST MONITORS CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS RECEIVING ANTIVIRAL THERAPY.

  • Transplantation
  • World
  • Market Size
  • CareDx, Inc.
  • Illumina, Inc.

The prominent features of this report are - ##.

  • Infectious Disease
  • Medical Biotechnology
  • Therapy
  • Transplantation
  • Chimerix, Inc.
  • May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

Day ##).

  • General Medicine And Specialty Medicine
  • Therapy
  • Transplantation
  • United States
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Protein Therapy
  • Therapy
  • Transplantation
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Drug Development
  • General Medicine And Specialty Medicine
  • Transplantation
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Protein Therapy
  • Therapy
  • Transplantation
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Immunology
  • Monoclonal Antibody
  • Transplantation
  • Novartis AG
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Liver Transplant
  • Therapy
  • Transplantation
  • Novartis AG

The country participated in only one trial.

  • Chemotherapy
  • Transplantation
  • Europe
  • North America
  • Product Initiative
  • May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

Day ##).

  • Digestive System Disorder
  • General Medicine And Specialty Medicine
  • Transplantation
  • United States
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Protein Therapy
  • Therapy
  • Transplantation
  • World
  • Product Initiative

## Phase I ## ## Preclinical ## ## Discovery ## ## Total ## ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Stage of Develop

  • Health Services
  • Therapy
  • Transplantation
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Leukemia
  • Transplantation
  • Novartis AG

Of ## clinical trials in various phases, ## trials are in phase ## and ## trials are in Phase ##/ phase ##. ## trials entered phase ## and ## trials are in Early Phase ##.

  • Clinical Trial
  • Lymphoma
  • Targeted Therapy
  • Transplantation
  • Product Initiative
  • JUN 23, 2017: BELLICUM ANNOUNCES CLINICAL DATA ON BPX-501 AT PRESIDENTIAL SYMPOSIUM OF THE 22ND CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
  • 5. All the trials included are unique trials.

The open-label, fixed-dose Phase ## clinical study (NCT##) evaluated the safety and preliminary efficacy of Viralym-C banked allogeneic CMV-specific T cells in a total of ## adult and pediatric HSCT recipients with refractory CMV infections that failed conventional antiviral t

  • Blood Disease
  • Medical Biotechnology
  • Transplantation
  • World
  • Product Initiative

Kidney Transplant Rejection - Overview Kidney Transplant Rejection - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR KIDNEY TRANSPLANT REJECTION, H## 2018 Pre-Registration ## ## Ph

  • Healthcare
  • Therapy
  • Transplantation
  • United States
  • Product Initiative

## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Sarah Cannon Research Institute LLC ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ##

  • Cancer
  • Clinical Trial
  • Transplantation
  • World
  • Product Initiative

SUBJECTS WERE FOLLOWED FOR A TOTAL OF ## DAYS FOR SAFETY AND ANTIVIRAL EFFECTS.

  • Healthcare
  • Medical Biotechnology
  • Transplantation
  • United States
  • Product Initiative

SUBJECTS WERE FOLLOWED FOR A TOTAL OF ## DAYS FOR SAFETY AND ANTIVIRAL EFFECTS.

  • Cell Therapy
  • Specialty Hospital
  • Therapy
  • Transplantation
  • Pluristem Therapeutics Inc.

Of ## clinical trials in various phases, ## trials are in phase ## and ## trials are in Phase ##/ phase ##. ## trials entered phase ## and ## trials are in Early Phase ##.

  • Clinical Trial
  • Lymphoma
  • Transplantation
  • North America
  • United States

SUBJECTS WERE FOLLOWED FOR A TOTAL OF ## DAYS FOR SAFETY AND ANTIVIRAL EFFECTS.

  • Healthcare
  • Medical Biotechnology
  • Transplantation
  • United States
  • Product Initiative
  • Product Development Milestones

" The recent introduction of highly successful antiviral treatments has provided new hope for patients infected with HCV, " said Conatus President and Chief Executive Officer, Steven J.

  • Cell Therapy
  • Healthcare
  • Therapy
  • Transplantation
  • Product Initiative
  • Liver Transplantation - Product Development Milestones

Mechanism of Action Digna Biotech is developing cardiotrophin-## (CT-##).

  • Digestive System Disorder
  • Liver Transplant
  • Therapy
  • Transplantation
  • Novartis AG